NASDAQSRPT

Hailshadow An advisory committee of the U.S. Department of Health and Human Services is expected to vote this fall on…

phive2015 Citi started coverage of Sarepta Therapeutics (NASDAQ:SRPT) with a buy rating, stating that it likes the risk/reward heading into…